{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=9&state=Virginia", "query": { "state": "Virginia", "city": "Fairfax", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 2551, "total_pages": 256, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=10&state=Virginia&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=8&state=Virginia&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T10:06:27.741Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05047536", "title": "KZR-261 in Subjects With Advanced Solid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumor" ], "interventions": [ { "name": "KZR-261", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kezar Life Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2021-09-30", "completion_date": "2025-01-17", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-20T10:06:27.741Z", "location_count": 12, "location_summary": "Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05047536" }, { "nct_id": "NCT01030432", "title": "Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "BMS-650032", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 285, "start_date": "2010-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-20T10:06:27.741Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030432" }, { "nct_id": "NCT03902184", "title": "IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, T-Cell", "Lymphoma, T-Cell, Cutaneous", "Mycosis Fungoides/Sezary Syndrome" ], "interventions": [ { "name": "IPH4102", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Innate Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2019-05-22", "completion_date": "2026-01-08", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-20T10:06:27.741Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03902184" }, { "nct_id": "NCT04566328", "title": "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma", "RISS Stage I Plasma Cell Myeloma", "RISS Stage II Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab and Hyaluronidase-fihj", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1450, "start_date": "2021-02-24", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-20T10:06:27.741Z", "location_count": 640, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 456 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566328" }, { "nct_id": "NCT06008093", "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 103, "start_date": "2024-04-04", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-20T10:06:27.741Z", "location_count": 47, "location_summary": "Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06008093" }, { "nct_id": "NCT02423070", "title": "Genome Transplant Dynamics", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Thoracic Organ Transplantation" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "14 Years to 80 Years" }, "enrollment_count": 991, "start_date": "2015-06-25", "completion_date": "2034-11-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-20T10:06:27.741Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02423070" }, { "nct_id": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "TTX-080", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tizona Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2020-07-14", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-20T10:06:27.741Z", "location_count": 41, "location_summary": "Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04485013" }, { "nct_id": "NCT04718779", "title": "A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Gaucher Disease" ], "interventions": [ { "name": "Digital Engagement Application (GD App)", "type": "OTHER" }, { "name": "No Intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-04-22", "completion_date": "2023-02-16", "has_results": true, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-10-20T10:06:27.741Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04718779" }, { "nct_id": "NCT01841762", "title": "Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Macitentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actelion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 284, "start_date": "2013-04-01", "completion_date": "2015-11-01", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-10-20T10:06:27.741Z", "location_count": 81, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01841762" }, { "nct_id": "NCT06720987", "title": "A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "KRAS G12C Mutation", "KRAS G12S Mutation", "Solid Tumor Malignancies", "CRC (Colorectal Cancer)" ], "interventions": [ { "name": "KQB365", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "KQB198", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kumquat Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2025-02-04", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-20T10:06:27.741Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06720987" } ] }